Dr. Willmott on FDA Approval of Maintenance Olaparib in Ovarian Cancer

Video

Lyndsay J. Willmott, MD, a gynecologic oncologist with Arizona Oncology, discusses the FDA approval of olaparib (Lynparza) in the maintenance setting for relapsed patients with platinum-sensitive ovarian cancer.

Lyndsay J. Willmott, MD, a gynecologic oncologist with Arizona Oncology, discusses the FDA approval of olaparib (Lynparza) in the maintenance setting for relapsed patients with platinum-sensitive ovarian cancer.

Related Videos
Jaime R. Merchán, MD
Erin Frances Cobain, MD
Mark D. Tyson, II, MD, MPH
Michael Iglesia, MD, PhD
Sundar Jagannath, MBBS
Jonathan E. Rosenberg, MD
Núria Agustí Garcia, MD
Erin Frances Cobain, MD
Kian-Huat Lim, MD, PhD
Joaquim Bellmunt, MD, PhD
Related Content
Stenoparib in Ovarian Cancer | Image Credit: © magicmine - stock.adobe.com

Phase 2 Trial Closure Clears a Path for Accelerated Development of Stenoparib in Ovarian Cancer

May 3rd 2024
Article
Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

April 20th 2023
Podcast
Gottfried E. Konecny, MD, medical oncologist, Department of Gynecologic Medical Oncology, lead clinician, gynecologic oncology, University of California, Los Angeles, UCLA Health Jonsson Comprehensive Cancer Center

PROs Underscore Utility of Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

April 29th 2024
Article
Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

July 18th 2022
Podcast
Sara Corvigno, MD, PhD

Understanding Chemotherapy-Related Clonal Hematopoiesis in Ovarian Cancer

April 27th 2024
Article
Shannon N. Westin, MD, MPH, FACOG

DENALI Study Seeks to Prove Efficacy of Azenosertib in High-Grade Serous Ovarian Cancer

April 26th 2024
Article